- Application for recombinant Insulin Human AF
- Front Page
- Onboarding of new employees
- Registrant group for Cetrimonium Bromide (CTAB)
- Registrant group for Reaction mass of C12 trimethylammonium bromide and C14 trimethylammonium bromide
- Registrant group for Tetradonium Bromide
- Applications for Quats
- Why us
- Download & Publications
- Contact us
Consistency is fundamental
We want to provides peace- of-mind to our customers, who can always feel secure with our operation and trust the quality of each delivery.
Our stable and well-established manufacturing, analytical and quality processes ensure continuous product consistency and availability. Therefore we deliver as promised, on-spec and on time.
Quality management system
The cornerstone of a quality organisation is an effective quality management system. Novo Nordisk Pharmatech’s quality management system is in compliance with DS/EN ISO 9001 in all of our activities.
We operate under the highest available standards, the ICH Q7 guideline for APIs, and we comply with all relevant quality ICH guidelines such as Q1, Q2, Q3, Q9, Q10, Q11 etc.
Our quality performance is continuously monitored by both customers and authorities, and we strive to continuously improve based on audit feed-back and customer centricity.
Our resources can help you keep development on track
Novo Nordisk Pharmatech A/S has more than 65 years of experience. Novo Nordisk Pharmatech specialises in supplying ingredients for the biopharmaceutical and pharmaceutical industries. We were established in 1949, acquired by Novo Nordisk in 1986 and have been part of the pharmaceutical group since then. With more than 90 years of experience within the biopharmaceutical industry, Novo Nordisk gives us access to a large number of in-house specilists who can assist with advice, even from early product development stages.
Our own highly qualified personal work contiously on product development and improving documentation to suit your needs. We also collaborate with internationally recognized experts. This expertise – together with product and documentation availability and global compliance – has made Novo Nordisk Pharmatech a preferred supplier with the major leading biopharmaceutical and pharmaceutical companies.
Sustainability and triple bottom line
Novo Nordisk is a member of the UN Global Compact and World Business Council for Sustainable Development (WBSCD). As a fully owned subsidiary, we follow the general policies of Novo Nordisk for sustainability, business ethics and code of conduct. We believe that a healthy economy, environment and society are fundamental to long-term business success. This is why we manage our business in accordance with the Triple Bottom Line (TBL) business principle, conducting activities in a financially, environmentally and socially responsible way.
Click below to read our: